[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metrorrhagia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metrorrhagia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100599372","phase-2-transdermal-ethinyl-estradiol-and-norelgestromin-for-irregular-bleeding-in-contraceptive-implant-users-100599372",false,"NCT07083635","Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant Users","Transdermal Ethinyl Estradiol and Norelgestromin for Treating Irregular Vaginal Bleeding in Contraceptive Implant Users: A Randomized, Double-Blind, Controlled Trial","Inclusion Criteria:\n\n* Women aged 18 years and older\n* Regular menstrual cycles : at least 1 cycle prior to contraceptive implant insertion\n* Normal pelvic examination and transvaginal ultrasound results\n* Normal cervical cancer screening within the past 3 years\n* Irregular vaginal bleeding defined as: Bleeding for more than 8 consecutive days, or Bleeding-free intervals of 15 days or less\n\nExclusion Criteria:\n\n* Previous treatment for irregular vaginal bleeding within the past 3 months\n* Pregnancy\n* Contraindications to estrogen or progestin use\n* Allergy to estrogen or progestin\n* Allergy to hormonal patches\n* Heavy vaginal bleeding causing anemia symptoms such as: Fatigue\u002FFainting\u002FDizziness","FEMALE","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to evaluate the effectiveness of transdermal contraceptive patches in treating irregular vaginal bleeding in women over 18 years old who are using contraceptive implants and experiencing abnormal vaginal bleeding. The main questions it aims to answer are:\n\n* Does transdermal ethinyl estradiol and norelgestromin patch effectively treat irregular vaginal bleeding caused by contraceptive implants compared to placebo?\n* What proportion of participants will report cessation of vaginal bleeding during treatment and remain bleeding-free at day 14 of treatment?\n* What is the safety profile and adherence rate of the transdermal patch treatment?\n\nResearchers will compare participants receiving active hormonal patches (ethinyl estradiol 600 mcg + norelgestromin 6 mg) to those receiving placebo patches to see if the hormonal treatment effectively stops irregular vaginal bleeding.\n\nParticipants will:\n\n* Apply transdermal patches for 21 days (changing patch every 7 days - total of 3 patches)\n* Attend follow-up visits at days 7, 14, 21, and 3 months (day 14 in-person, others via telephone)\n* Complete bleeding diaries and report any side effects\n* Follow-up schedule:\n\nDay 7: Telephone follow-up to assess bleeding pattern, side effects, and patch adherence Day 14: In-person visit at the clinic for comprehensive evaluation including bleeding assessment, side effects monitoring, and adherence check Day 21: Telephone follow-up to evaluate treatment completion, ongoing bleeding status, and need for additional treatment 3 months: Final telephone follow-up to assess long-term outcomes and recurrence of bleeding",[26,27,28,29],"Menstruation Disturbances","Metrorrhagia","Uterine Hemorrhage","Contraception Behavior",[31,32,33,34,35,36,37,38,39,40,41],"Contraceptive implant","Abnormal vaginal bleeding","Bothersome vaginal bleeding","Irregular vaginal bleeding","Transdermal hormonal contraception","Ethinyl estradiol","Norelgestromin","Abnormal uterine bleeding","Contraceptive-induced bleeding","Combined hormonal contraception","Hormonal contraceptive patch","RECRUITING","2025-12-09",{"date":45,"type":46},"2025-12-10","ACTUAL",{"date":48,"type":46},"2025-07-29",{"date":50,"type":20},"2026-12",{"name":52,"class":53},"Chulalongkorn University","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":21,"phases":66,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":54},"100577738","a-randomized-study-comparing-subtotal-vs-total-hysterectomy-long-term-outcomes-100577738","NCT06802198","A Randomized Study Comparing Subtotal vs Total Hysterectomy Long Term Outcomes","Comparison of Long-Term Outcomes Following Laparoscopic Total Vs Supracervical Hysterectomy, a Randomized Clinical Trial","STORY","Inclusion Criteria:\n\n* Age\\>18 years\n* Signed informed consent\n\nExclusion Criteria:\n\n* Uterine or adnexal pathology suspect for malignancy\n* Abnormal or unknown PAP test\n* Patients with invasive neoplasia in the previous 5 years (excluding non-melanoma skin tumors, breast cancer T1 N0 M0 Grade 1 or 2 without signs of recurrence or activity).\n* Previous radical pelvic surgery or radiotherapy;\n* Age \\> 80 years\n* Pregnant patients\n* Desire for further pregnancies\n* Contraindications to general anaesthesia or to the Trendelenburg position\n* Refusal to sign informed consent","80 Years",{"count":65,"type":20},500,[67],"NA","The goal of this randomized clinical trial is to assess the outcomes of total laparoscopic hysterectomy vs subtotal laparoscopic hysterectomy + mini-laparotomy for uterine extraction for benign gynecological conditions in terms of change in quality of life at 36 months after surgery and patient's impression of improvement. The secondary objectives of the study are to assess any differences in terms of peri and postoperative outcomes (postoperative pain, blood loss, hospital stay, intraoperative or short and long-term postoperative complications, long term urinary, bowel and pelvic floor symptoms, prevalence of vaginal cuff dehiscence).\n\nParticipants will fill the following questionnaires pre-operatively and at the follow up:\n\n* Short Form 36 (SF36),\n* Euro Quality of life 5D-3L (EQ 5D-3L)\n* Female Sexual Function Index (FSFI)\n* Patient Global Impression of Improvement (PGI-I) only during the follow-up period.",[70,27,71,72,73,74],"Fibroid Uterus","Adenomyosis","Benign Gynecologic Neoplasm","Endometriosis","Abnormal Uterine Bleeding","NOT_YET_RECRUITING","2025-09-04",{"date":78,"type":46},"2025-09-05",{"date":80,"type":20},"2025-10-01",{"date":82,"type":20},"2030-02-01",{"name":84,"class":53},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS"]